Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT + Temozolomide + Irinotecan for Glioblastoma
NCT00099125Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Nov 2004
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in glioblastoma multiforme (GBM), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 18 months. Started Nov 2004; status: completed.
02
Drugs
irinotecan
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00099125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099125.